Drug intelligence / Profile preview

YGX2

Development stage: Preclinical
Lead developer: Youngene Therapeutics
Modality: Small Molecules

Overview

YGX2 is a small molecule drug candidate developed by Youngene Therapeutics. It is currently in preclinical development and has been investigated for the treatment of gout and nonalcoholic steatohepatitis (NASH). The drug is being explored for use in therapeutic areas including congenital disorders, digestive system disorders, and endocrinology/metabolic diseases. As of the latest update, no detailed mechanism of action or molecular target has been disclosed publicly[1].

Beyond the preview

Go deeper on YGX2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YGX2.

Explore the full profile